Authors

Baptist Health Adopts Innovative AI Solutions, Cutting-Edge Research to Address Complexities of Care

The rapid progress in oncology, along with complex cases and rising costs, presents challenges in delivering high-quality cancer care.

Improving Access to Bone Marrow Transplant and Cellular Therapies

Stem cell treatments offer hope for a variety of conditions. However, access to these potentially life-altering procedures is often hampered by social factors such as socioeconomic status, race, cultural background, and geographic location.

Ra-223 Demonstrates Safety, Efficacy in Managing Bone Metastases in Prostate Cancer

Patients diagnosed with bone metastatic, castration-resistant prostate cancer and treated with radium-223 showed lower incidences of treatment-related adverse events or treatment discontinuation, particularly when used in the front-line setting.

Model for MA Plan Reimbursement Needs Second Look

Addressing issues such as congestive heart failure is important to providing safe care to patients with cancer.

Mitigating Health Care Cyberattacks: 5 Best Practices

Health care organizations face a growing wave of cyberattacks and must implement strong defenses to protect patient data and ensure operational continuity.

MR-LINAC Provides Greater Precision With Adaptive Radiation Across Cancers

Paul B. Renz, DO, discussed the ideal uses of MR-LINAC in pancreatic, prostate, liver, head and neck, and rectal cancers.

10 Years in CLL: Top Advances From 2012-2022

The past decade has seen the FDA approve a handful of new targeted therapies for chronic lymphocytic leukemia that are prompting a move toward chemotherapy-free treatment of the disease.

Differentiating Pseudoprogression From Hyperprogression in Patients Treated With Immunotherapies

Advances in the field have also led to the recognition of other clinical challenges, including unforeseen observations and complications associated with choosing the sequencing of appropriate therapeutic interventions as well as the management of drug-related complications.

Ibrutinib Plus Venetoclax May Be an Effective Treatment for Previously Untreated WM

Fast and durable response were seen in patients with Waldenström Macroglobulinemia who received the combination of ibrutinib and venetoclax.

Breast Cancer Awareness Month: What to Know for Different Types of Breast Cancer

For Breast Cancer Awareness Month Kristina Mirabeau-Beale, mD, MPH, and Bridget Koontz, MD, discuss the different types of breast cancer that clinicians need to be aware of.

Long-Term Management of Patients with P53 Aberrations

Treatment approaches to address mutations or deletions of chromosome 17p are needed due to the surfacing of point mutations, including TP53 aberrations in chronic lymphocytic leukemia.

Liquid Biopsy Holds Promise in Prostate Cancer Diagnosis

According to Joshua M. Lang, MD, MS, the importance of molecular understanding, especially in initially focusing on the genetics of PCa and how that can inform new therapies, has been one of the revolutions in PCa.

Risk-Based Treatment of Hodgkin Lymphoma in the Era of Novel Therapies

Despite complete remission rates of up to 90%, late toxicities, such as secondary malignancies and cardiovascular events, are key concerns in patients treated for early-stage Hodgkin lymphoma.

Evaluating the Link Between COVID-19 and Cancer Progression in 2023

KEYMAKER-U03: Belzutifan Triplet Shows Efficacy Edge in 1L ccRCC

New triplet therapy combining belzutifan, pembrolizumab, and lenvatinib shows promising efficacy for advanced clear cell renal cell carcinoma, outperforming other regimens.

Building a Patient-Centered Ecosystem Leads to Better Care

Within the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.

Challenges of Breast Cancer in Young Adults

According to Jane Méndez, M.D., FACS, special considerations come into play when diagnosing and treating young adults with breast cancer.

Management of HR+, HER2- Early-Stage Breast Cancer After Diagnosis

Physicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.

Talquetamab/Daratumumab Demonstrates Promising Efficacy in Relapsed/Refractory Multiple Myeloma

In TRIMM-2, an overall response rate of 82% was seen amon patients given talquetamab plus daratumumab and pomalidomide in patients with relapsed/refractory multiple myeloma.

MRD in Ph+ ALL: How Do You Measure It and What Does It Mean?

Although it is well-established that MRD negativity plays an important prognostic role in Ph-positive ALL, the optimal method to assess MRD in this disease and how to use this information therapeutically are still being established.

Expanding 177Lutetium-PSMA-617 Use in the Community

Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.

Metastatic Breast Cancer Awareness Day: Assessing the Role of ADCs

Muhammad Imam, MD, reviews the use of newer antibody-drug conjugates for patients with metastatic breast cancer across subtypes.

Considerations for Treatment of Advanced/Metastatic EGFR-mutated NSCLC

An expert shares clinical pearls with the community, offering insights and tips for managing patients effectively.

Previous Liver Infection Requires a Rapid and Flexible Treatment Response in NSCLC

Jorge A. Rios, MD, a medical oncologist at Zangmeister Cancer Center in Columbus, Ohio, part of the American Oncology Network, shared the case of a woman who developed multiple severe adverse events attributable to durvalumab.

World Pancreatic Cancer Awareness Day: Advances in Pancreatic Cancer Detection and Treatment

Lynn M. Matrisian, PhD, MBA, and Allison Rosenzweig, PhD, from Pancreatic Cancer Action Network, review advances in the pancreatic cancer setting for World Pancreatic Cancer Awareness Day.

Immunotherapy Offers Hopeful Outcomes in Nonmelanoma Skin Cancers

New and emerging treatment modalities for advanced nonmelanoma skin cancer provide hope for this patient subset.